GoodRx Partners with Eli Lilly to Expand Access to New GLP-1 Weight Management Drugs
Event summary
- GoodRx and Eli Lilly are expanding access to Foundayo™ (orforglipron), a newly FDA-approved oral GLP-1 medication, at $149 per month for self-pay patients.
- Zepbound® (tirzepatide) KwikPen® is also available through GoodRx at $299 per month at over 70,000 pharmacies nationwide.
- The partnership aims to provide transparent pricing and nationwide pharmacy access for weight management treatments outside traditional insurance pathways.
- GoodRx serves nearly 25 million consumers and over one million healthcare professionals annually.
The big picture
This partnership reflects a broader industry shift towards direct-to-consumer access models for medications, particularly GLP-1 treatments prescribed for weight loss. With insurance coverage for such treatments often inconsistent or unavailable, manufacturers are increasingly exploring alternative pathways to reach patients. GoodRx's role in this ecosystem underscores its strategic position at the intersection of consumers, healthcare professionals, and pharmaceutical companies, facilitating broader access to innovative therapies.
What we're watching
- Market Adoption
- How the availability of transparent cash pricing will affect the adoption of GLP-1 treatments among self-pay patients.
- Competitive Dynamics
- Whether GoodRx can sustain its leadership in prescription savings as more manufacturers explore direct-to-consumer access models.
- Regulatory Shifts
- The pace at which regulatory frameworks adapt to new access models for innovative therapies, particularly in weight management.
Related topics